168 related articles for article (PubMed ID: 20224916)
1. N-terminally fusion of Her2/neu to HSP70 decreases efficiency of Her2/neu DNA vaccine.
Pakravan N; Soudi S; Hassan ZM
Cell Stress Chaperones; 2010 Sep; 15(5):631-8. PubMed ID: 20224916
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant activity of GP96 C-terminal domain towards Her2/neu DNA vaccine is fusion direction-dependent.
Pakravan N; Hashemi SM; Hassan ZM
Cell Stress Chaperones; 2011 Jan; 16(1):41-8. PubMed ID: 20730610
[TBL] [Abstract][Full Text] [Related]
3. A novel vaccine strategy to induce mycobacterial antigen-specific Th1 responses by utilizing the C-terminal domain of heat shock protein 70.
Uto T; Tsujimura K; Uchijima M; Seto S; Nagata T; Suda T; Chida K; Nakamura H; Koide Y
FEMS Immunol Med Microbiol; 2011 Mar; 61(2):189-96. PubMed ID: 21204994
[TBL] [Abstract][Full Text] [Related]
4. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.
Wang B; Zaidi N; He LZ; Zhang L; Kuroiwa JM; Keler T; Steinman RM
Breast Cancer Res; 2012 Mar; 14(2):R39. PubMed ID: 22397502
[TBL] [Abstract][Full Text] [Related]
5. Comparison of adjuvant activity of N- and C-terminal domain of gp96 in a Her2-positive breast cancer model.
Pakravan N; Hassan ZM
Cell Stress Chaperones; 2011 Jul; 16(4):449-57. PubMed ID: 21359667
[TBL] [Abstract][Full Text] [Related]
6. Efficient induction of a Her2-specific anti-tumor response by dendritic cells pulsed with a Hsp70L1-Her2(341-456) fusion protein.
Fu Q; Wu Y; Yan F; Wang N; Wang W; Cao X; Wang Y; Wan T
Cell Mol Immunol; 2011 Sep; 8(5):424-32. PubMed ID: 21785448
[TBL] [Abstract][Full Text] [Related]
7. HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice.
Manjili MH; Wang XY; Chen X; Martin T; Repasky EA; Henderson R; Subjeck JR
J Immunol; 2003 Oct; 171(8):4054-61. PubMed ID: 14530326
[TBL] [Abstract][Full Text] [Related]
8. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic HER2/Neu DNA vaccine inhibits mouse tumor naturally overexpressing endogenous neu.
Lin CC; Chou CW; Shiau AL; Tu CF; Ko TM; Chen YL; Yang BC; Tao MH; Lai MD
Mol Ther; 2004 Aug; 10(2):290-301. PubMed ID: 15294176
[TBL] [Abstract][Full Text] [Related]
10. CCL19 as an adjuvant for intradermal gene gun immunization in a Her2/neu mouse tumor model: improved vaccine efficacy and a role for B cells as APC.
Nguyen-Hoai T; Hohn O; Vu MD; Baldenhofer G; Sayed Ahmed MS; Dörken B; Norley S; Lipp M; Pezzutto A; Westermann J
Cancer Gene Ther; 2012 Dec; 19(12):880-7. PubMed ID: 23099886
[TBL] [Abstract][Full Text] [Related]
11. Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/neu extracellular domain plus anti-HER2/neu IgG3-(IL-2) or anti-HER2/neu IgG3-(GM-CSF) fusion protein.
Dela Cruz JS; Morrison SL; Penichet ML
Vaccine; 2005 Sep; 23(39):4793-803. PubMed ID: 15967544
[TBL] [Abstract][Full Text] [Related]
12. Modified HPV16 E7/HSP70 DNA vaccine with high safety and enhanced cellular immunity represses murine lung metastatic tumors with downregulated expression of MHC class I molecules.
Li H; Ou X; Xiong J
Gynecol Oncol; 2007 Mar; 104(3):564-71. PubMed ID: 17081598
[TBL] [Abstract][Full Text] [Related]
13. A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 gene enhanced potency of HBV DNA vaccine.
Li X; Yang X; Li L; Liu H; Liu J
Vaccine; 2006 Apr; 24(16):3321-31. PubMed ID: 16472546
[TBL] [Abstract][Full Text] [Related]
14. Immunization with a HSP65-HER2 fusion peptide selectively eliminates HER2(+) B16 melanoma cells in a xenograft tumor mouse model.
Wang J; Wang X; Chen Y; Wan M; Xiang Z; Wu X; Wei H; Wang L; Zhang P; Wang L; Yu Y
Tumour Biol; 2013 Feb; 34(1):193-201. PubMed ID: 23055194
[TBL] [Abstract][Full Text] [Related]
15. Heterologous human/rat HER2-specific exosome-targeted T cell vaccine stimulates potent humoral and CTL responses leading to enhanced circumvention of HER2 tolerance in double transgenic HLA-A2/HER2 mice.
Xie Y; Wu J; Xu A; Ahmeqd S; Sami A; Chibbar R; Freywald A; Zheng C; Xiang J
Vaccine; 2018 Mar; 36(11):1414-1422. PubMed ID: 29415817
[TBL] [Abstract][Full Text] [Related]
16. Co-administration of GP96 and Her2/neu DNA vaccine in a Her2 breast cancer model.
Pakravan N; Langroudi L; Hajimoradi M; Hassan ZM
Cell Stress Chaperones; 2010 Nov; 15(6):977-84. PubMed ID: 20544406
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of vaccination with plasmid DNA encoding for HER2/neu or HER2/neu-eGFP fusion protein against prostate cancer in rats.
Bhattachary R; Bukkapatnam R; Prawoko I; Soto J; Morgan M; Salup RR
Int Immunopharmacol; 2002 May; 2(6):783-96. PubMed ID: 12095169
[TBL] [Abstract][Full Text] [Related]
18. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.
Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J
Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129
[TBL] [Abstract][Full Text] [Related]
19. Protective efficacy of a DNA vaccine construct encoding the VP2 gene of infectious bursal disease and a truncated HSP70 of Mycobacterium tuberculosis in chickens.
Maity HK; Dey S; Mohan CM; Khulape SA; Pathak DC; Vakharia VN
Vaccine; 2015 Feb; 33(8):1033-9. PubMed ID: 25596458
[TBL] [Abstract][Full Text] [Related]
20. A novel chimeric DNA vaccine: enhancement of preventive and therapeutic efficacy of DNA vaccine by fusion of Mucin 1 to a heat shock protein 70 gene.
Choi DH; Woo JK; Choi Y; Seo HS; Kim CW
Mol Med Rep; 2011; 4(5):885-90. PubMed ID: 21725596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
